Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Alcoholic hepatitis)
10,323 results
  • Autoimmune Hepatitis Leading to Liver Cirrhosis: A Case Report. [Journal Article]
    JNMA J Nepal Med Assoc. 2022 Dec 01; 60(256):1059-1062.Shrestha M, Subedi SC, … Mehta N
  • Autoimmune hepatitis is a rare form of chronic liver inflammation that begins as acute hepatitis and progresses to chronic liver disease. It presents with varied clinical features from acute hepatitis to chronic liver diseases like chronic viral hepatitis and alcoholic liver disease, making it difficult to diagnose in the absence of a high index of suspicion and adequate laboratory support. Autoi…
  • Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis. [Review]
    Front Pharmacol. 2022; 13:1071844.Li L, Zhu Z
  • Liver fibrosis, which is characterized by the excessive deposition of extracellular matrix (ECM) materials (primarily fibrillar collagen-I), is an abnormal repair reaction and pathological outcome of chronic liver diseases caused by alcohol abuse, non-alcoholic fatty liver disease, and chronic hepatitis B and C virus infections. Liver fibrosis often progresses to liver cirrhosis and hepatocellula…
  • The Preventive and Therapeutic Potential of the Flavonoids in Liver Cirrhosis: Current and Future Perspectives. [Review]
    Chem Biodivers. 2023 Jan 26 [Online ahead of print]Sahu R, Goswami S, … Rawal RK
  • Non-alcoholic fatty liver disease (NAFLD) may vary from moderately mild non-alcohol fatty liver (NAFL) towards the malignant variant known as non-alcoholic steatohepatitis (NASH), which is marked by fatty liver inflammation and may progress to liver cirrhosis (LC), liver cancer, fibrosis, or liver failure. Flavonoids can protect the liver from toxins through their anti-inflammatory, antioxidant, …
  • Acute-on-chronic liver failure: Controversies and consensus. [Review]
    World J Gastroenterol. 2023 Jan 14; 29(2):232-240.Ngu NLY, Flanagan E, … Le ST
  • Acute-on-chronic liver failure (ACLF) is a poorly defined syndrome characterised by rapid clinical deterioration in patients with chronic liver disease. Consequences include high short-term morbidity, mortality, and healthcare resource utilisation. ACLF encompasses a dysregulated, systemic inflammatory response, which can precipitate extra hepatic organ failures. Common precipitants include infec…
  • COVID-19 and liver injury: An ongoing challenge. [Review]
    World J Gastroenterol. 2023 Jan 14; 29(2):257-271.Papagiouvanni I, Kotoulas SC, … Goulis I
  • The new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in December 2019, in Wuhan, China. The virus was rapidly spread worldwide, causing coronavirus disease 2019 (COVID-19) pandemic. Although COVID-19 is presented, usually, with typical respiratory symptoms (i.e., dyspnea, cough) and fever, extrapulmonary manifestations are also encountered. Liver injury …
  • PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales. [Review]
    J Transl Autoimmun. 2023; 6:100188.Colapietro F, Gershwin ME, Lleo A
  • Primary biliary cholangitis (PBC) is an autoimmune liver disease involving the small intrahepatic bile ducts; when untreated or undertreated, it may evolve to liver fibrosis and cirrhosis. Ursodeoxycholic Acid (UDCA) is the standard of care treatment, Obeticholic Acid (OCA) has been approved as second-line therapy for those non responder or intolerant to UDCA. However, due to moderate rate of UDC…
  • Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. [Review]
    World J Gastroenterol. 2023 Jan 07; 29(1):61-74.Lee S, Saffo S
  • Cirrhosis is a leading cause of morbidity and mortality, impacting more than 120 million people worldwide. Although geographic differences exist, etiologic factors such as alcohol use disorder, chronic viral hepatitis infections, and non-alcoholic fatty liver disease are prevalent in nearly every region. Historically, significant effort has been devoted to modifying these risks to prevent disease…
  • Metabolic Role of Autophagy in the Pathogenesis and Development of NAFLD. [Review]
    Metabolites. 2023 Jan 07; 13(1)An L, Wirth U, … Kühn F
  • Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disease, ranging from simple steatosis to hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Liver fibrosis, which portends a poor prognosis in NAFLD, is characterized by the excessive accumulation of extracellular matrix (ECM) proteins resulting from abnormal wound repair response and metabolic disorders. Various m…
  • Histone methylation in pre-cancerous liver diseases and hepatocellular carcinoma: recent overview. [Review]
    Clin Transl Oncol. 2023 Jan 17 [Online ahead of print]Charidemou E, Koufaris C, … Rubio-Tomás T
  • Hepatocellular carcinoma (HCC) is the prevalent form of liver cancer in adults and the fourth most common cause of cancer-related death worldwide. HCC predominantly arises in the context of cirrhosis as a result of chronic liver disease, injury and inflammation. Full-blown HCC has poor prognosis because it is highly aggressive and resistant to therapy. Consequently, interventions that can prevent…
  • [Developments in Research on the Relationship Between Porphyromonas gingivalis and Non-Oral Diseases]. [Review]
    Sichuan Da Xue Xue Bao Yi Xue Ban. 2023 Jan; 54(1):20-26.Zhang KK, Sun Y, Pan YH
  • Porphyromonas gingivalis (P. gingivalis) is a common periodontal pathogen. Recently, there has been increasing evidence suggesting that P. gingivalis is not only a common pathogen in the oral cavity, but is also closely associated with non-oral diseases, including inflammatory bowel disease, cancer, cardiovascular diseases, Alzheimer's disease, rheumatoid arthritis, diabetes mellitus, premature b…
  • Spectrum, Screening, and Diagnosis of Alcohol-related Liver Disease. [Review]
    J Clin Exp Hepatol. 2023 Jan-Feb; 13(1):75-87.Hernandez-Tejero M, Clemente-Sanchez A, Bataller R
  • Alcohol-related liver disease (ALD) represents one of the leading causes of chronic liver disease and is a major cause of liver-related deaths worldwide. ALD encompasses a range of disorders including simple steatosis, alcoholic steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Patients with underlying ALD and continued heavy alcohol consumption can also develop an episode of ac…
  • Liver Transplantation in Alcohol-related Liver Disease and Alcohol-related Hepatitis. [Review]
    J Clin Exp Hepatol. 2023 Jan-Feb; 13(1):127-138.Ntandja Wandji LC, Ningarhari M, … Louvet A
  • Alcohol-related liver disease (ARLD) remains one of the leading causes of chronic liver disease and the prevalence of alcohol-related cirrhosis is still increasing worldwide. Thus, ARLD is one of the leading indications for liver transplantation (LT) worldwide especially after the arrival of direct-acting antivirals for chronic hepatitis C infection. Despite the risk of alcohol relapse, the outco…
  • Artificial Intelligence in Hepatology- Ready for the Primetime. [Review]
    J Clin Exp Hepatol. 2023 Jan-Feb; 13(1):149-161.Kalapala R, Rughwani H, Reddy DN
  • Artificial Intelligence (AI) is a mathematical process of computer mediating designing of algorithms to support human intelligence. AI in hepatology has shown tremendous promise to plan appropriate management and hence improve treatment outcomes. The field of AI is in a very early phase with limited clinical use. AI tools such as machine learning, deep learning, and 'big data' are in a continuous…
  • Emerging Pharmacotherapies in Alcohol-Associated Hepatitis. [Review]
    J Clin Exp Hepatol. 2023 Jan-Feb; 13(1):116-126.Wakil A, Niazi M, … Pyrsopoulos NT
  • CONCLUSIONS: A combination of therapies was investigated, possibly providing a synergistic effect of drugs with different mechanisms. Multiple clinical trials of novel therapies in AH remain ongoing. Their result could potentially make a difference in the clinical course of the disease. DUR-928 and granulocyte colony-stimulating factor had promising results and further trials are ongoing to evaluate their efficacy in the large patient sample.
  • Epidemiology and Disease Burden of Alcohol Associated Liver Disease. [Review]
    J Clin Exp Hepatol. 2023 Jan-Feb; 13(1):88-102.Aslam A, Kwo PY
  • Consumption of alcohol in excess leads to substantial medical, economic, and societal burdens. Approximately 5.3% of all global deaths may be attributed to alcohol consumption. Moreover, the burden of alcohol associated liver disease (ALD) accounts for 5.1% of all disease and injury worldwide. Alcohol use disorder (AUD) affects men more than women globally with significant years of life loss to d…
  • Unraveling the Emerging Niche Role of Hepatic Stellate Cell-derived Exosomes in Liver Diseases. [Review]
    J Clin Transl Hepatol. 2023 Apr 28; 11(2):441-451.Yin KL, Li M, … Liao R
  • Hepatic stellate cells (HSCs) play an essential role in various liver diseases, and exosomes are critical mediators of intercellular communication in local and distant microenvironments. Cellular crosstalk between HSCs and surrounding multiple tissue-resident cells promotes or inhibits the activation of HSCs. Substantial evidence has revealed that HSC-derived exosomes are involved in the occurren…
New Search Next